I read it carefully. It does have two "typos" (a repeated paragraph and a key word missing "week ----".) Someone mentioned it does not tackle the extended trial outcome data - OLE. Data which I remember as being pretty good. So that's a perhaps damning omission. The guy does make a good case for all the oddities in the history of Missling's reporting on the trial data over a long 14 months, but that could be because he wanted that OLE data.
My feeling after finishing the thing was that it really shouldn't get approved, but having been alerted to the OLE data not having been considered by the guy at all, and the fact that some 50 so-called experts somehow "signed on" to the peer reviewed article on the trial, the fact it's a daily pill and there's nothing else out there really, I'm willing to gamble that it does get an approval but that the EMA does an FDA type thing and requires a confirmatory trial to start post-haste .... and that's why we are going to raise that 300 million.
I think the EMA is going to swallow hard and take a big chance on us and move on as fast as possible to something else and hope no one raises too much of a fuss. And so I also have a feeling that we'll get that approval asap. Like maybe even next week!!!
So I'm going out on the same limb as I think the EMA will.
(And with both of us on that limb, it'll probably break ... and we'll both tumble down .... but by then I will have sold and they probably will have too.)
AI
Market Data 
Markets 
